MaxCyte Investor Presentation Deck

2023 Summary and 2024 YTD Achievements ● ● ● 1 ● Prepare/Isolate 2023 Achievements Five SPL partnerships announced in 2023: 2 Concentrate Prime Medicine in August, Lyell Immunopharma and Vittoria Biotherapeutics in July, Walking Fish Therapeutics in May and Catamaran Bio in January • Published Inaugural ESG 2023 Summary Report in May ● Douglas J. Swirsky appointed MaxCyte's Chief Financial Officer, bringing over two decades of experience in the healthcare sector, including as a public company executive at Nasdaq-listed organizations First MaxCyte-Enabled Therapy is Approved Vertex/ CRISPR's Exa-cel (CASGEVYTM) for Sickle Cell Disease (UK + US) and for Beta-Thalassemia (UK) 3 ● 20 4 ● Culture 5 Cryopreserve M MaxCyte 6 Thaw/Dose 2024 YTD Achievements Maher Masoud appointed MaxCyte's President and Chief Executive Officer, bringing more than 25 years of experience in the biopharmaceutical industry, including 17 years as an attorney and general counsel SPL Partnership Announced with Lion TCR in January Lion TCR to use MaxCyte's Flow Electroporation® technology and EXPERT™ platform to develop and scale TCR-T cell therapies for solid tumors and viral-related diseases SPL Partnerships now stands at 24 © 2023 MaxCyte, Inc. All Rights Reserved

View entire presentation